Biography for John Carroll
John D. Carroll is a biotech analyst with 34 years of prize-winning experience in journalism. Appointed editor of FierceBiotech in 2003, he has covered genomics, biotechnology, healthcare and other business topics for Managed Care, American Banker, Small Times, and Local Business.com, He has also contributed stories from Central America and Ireland to the Dallas Morning News and Time and wrote for the Houston Press and other leading publications. He spent six years as editor and publisher of the Dallas Business Journal, was publisher of Texas Business and early in his career was part of a Pulitzer Prize-winning team of reporters and editors at the Kansas City Star & Times. He enjoys hiking, traveling and spending time with his family. Carroll is based in Vermont and Texas and can be reached at email@example.com. Follow @JohnCFierce on Twitter.
Articles by John Carroll
Clinical research organizations operating in Europe may soon get some help from EU officials.
The contracting coup comes four months after Amgen ($AMGN) tied up with Watson ($WPI) on an ambitious pact to develop biosimilars of some leading cancer therapies.
Quintiles has agreed to start promoting access to Archimedes' computer simulation model.
News that tiny FerroKin BioSciences earned a big buyout deal with Shire ($SHPGY) has helped spotlight the growing popularity of the virtual biotech model.
Albany Molecular Research has announced plans to close a facility in Budapest, Hungary, axing 100 jobs in the process.
Ventria Bioscience has scored a supply deal with Merck KGaA.
If there's one thing that Novartis ($NVS) CEO Joe Jimenez likes to talk about, it's efficiency.
Animal rights activists in the U.K. is gaining traction in their campaign to stop the transportation of mice, rats and rabbits into the country for R&D purposes.
One of the big discussions in biotech in recent years has centered on the virtual business model. With IPOs hard to pull off, it just made more sense to many in the venture community to back a new generation of small developers with one or two programs that could be pushed into mid-stage development and then sold off. A host of global outsourcers made it possible to efficiently stage clinical studies.
The medical schools at Columbia University and Weill Cornell have signed on with an ambitious NIH-backed effort that has been crafting a national support system for investigators pursuing mid-stage studies for neuroscience treatments.